US Stock Market Move | ZAI LAB (ZLAB.US) rises more than 5%. New drug repotrectinib approved for listing in Taiwan region.

On Tuesday, Zai Lab (ZLAB.US) rose more than 5%, closing at $33.53 per share. In terms of news, Zai Lab recently announced that the drug regulatory agency in Taiwan has approved its new drug, repotrectinib, for market authorization. This drug is mainly used to treat ROS1-positive locally advanced or metastatic non-small cell lung cancer in adult patients, as well as solid tumor adult patients with NTRK gene fusion. The innovative drug, known as Okale in mainland China, has received approval which signifies an important step for Zai Lab in expanding its market and reaching more patients. The launch of repotrectinib will provide new treatment options for cancer patients and further enrich clinical treatment methods.